Rapid Outbreak Response
& Therapeutics
Agility in the face of emerging threats. Utilizing the DNDi (Drugs for Neglected Diseases initiative) model, we bypass decades of traditional drug discovery. By screening and repurposing FDA-approved drugs against novel pathogen targets, and validating them through advanced PK/PD testing and in vivo vector models, we deliver safety-validated, bedside-ready antimicrobial cocktails in months, not years.
MTB Platform
Precision Tuberculosis Surveillance
A genomic epidemiology system designed to interrupt TB transmission. The MTB Platform tracks circulating strains and detects outbreak clusters across Thailand with high resolution. By integrating lineage tracking with predictive drug-resistance profiling, it empowers public health officials to shift from passive monitoring to proactive intervention.
PathGS Sepsis Platform
Rapid Hospital Infection Control
An end-to-end pathogen genomic surveillance (PathGS) solution for hospital environments. This platform accelerates the identification of sepsis-causing agents and AMR genes through rapid DNA sequencing. It provides infection control teams with the immediate, precise data needed to optimize treatment plans and contain hospital-acquired infections.
GEC-AMR Platform
The National AMR Intelligence Hub
Thailand’s comprehensive Genomic Epidemiological Center (GEC) for AMR. This centralized database democratizes access to complex bioinformatics, offering a user-friendly interface for stakeholders at all levels. It aggregates national-scale genomic data to identify resistance mechanisms and emerging superbugs, supporting policy-making and regional surveillance efforts.
High-Affinity Dengue Antibodies
Biological Reagents
Optimized for Assay Development & Therapeutic Research. We offer a catalog of high-specificity monoclonal antibodies characterized for Dengue virus serotypes. These biological reagents are validated for high-performance applications, including:
Diagnostic Kit Development: Ideal for enhancing sensitivity in Lateral Flow Assays (LFA) and ELISA platforms.
Vaccine & Therapeutic Research: Validated for epitope mapping and neutralization studies.Â
Available for licensing and collaborative R&D.
